MARKET

NAMS

NAMS

NewAmsterdam Pharma Company N.V
NASDAQ
26.67
-1.16
-4.17%
After Hours: 26.67 0 0.00% 16:15 08/13 EDT
OPEN
27.85
PREV CLOSE
27.83
HIGH
28.03
LOW
26.63
VOLUME
1.22M
TURNOVER
--
52 WEEK HIGH
42.21
52 WEEK LOW
23.05
MARKET CAP
3.19B
P/E (TTM)
-12.4197
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at NAMS last week (0803-0807)?
Weekly Report · 3d ago
Needham Remains a Buy on NewAmsterdam Pharma Company (NAMS)
TipRanks · 6d ago
NewAmsterdam Pharma Is Maintained at Outperform by RBC Capital
Dow Jones · 08/06 17:55
NewAmsterdam Pharma Price Target Cut to $50.00/Share From $51.00 by RBC Capital
Dow Jones · 08/06 17:55
RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50
Benzinga · 08/06 17:46
Analysts Offer Insights on Healthcare Companies: Arcus Biosciences (RCUS), NewAmsterdam Pharma Company (NAMS) and Revolution Medicines (RVMD)
TipRanks · 08/06 13:30
Stifel Nicolaus Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
TipRanks · 08/06 12:01
Pantginis Reiterates Buy on NewAmsterdam, Maintains $52 12-Month Price Target Amid Key Obicetrapib Catalysts
TipRanks · 08/06 10:36
More
About NAMS
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.

Webull offers NewAmsterdam Pharma Company NV stock information, including NASDAQ: NAMS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NAMS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NAMS stock methods without spending real money on the virtual paper trading platform.